Inactive Instrument

Jounce Therapeutics, Inc.

Equities

JNCE

US4811161011

Biotechnology & Medical Research

Jounce Therapeutics : to Participate in a Fireside Chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference

November 26, 2020 at 09:09 am EST

Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Richard Murray, Ph.D., chief executive officer and president, and Elizabeth Trehu, M.D., chief medical officer, will participate in a fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference.

A pre-recorded fireside chat will be available beginning on Tuesday, December 1, 2020 at 8:00 a.m. ET and can be viewed by visiting 'Events & Presentations' in the Investors and Media section of Jounce's website at www.jouncetx.com. A replay of the webcast will be archived for 30 days.

About Jounce Therapeutics

Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. Jounce's most advanced product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS, and is currently being studied in the SELECT Phase 2 trial. JTX-4014 is a PD-1 inhibitor intended for combination use in the SELECT trial and with Jounce's broader pipeline. Jounce's next development stage product candidate, JTX-8064, is a LILRB2 (ILT4) receptor antagonist shown to reprogram immune-suppressive tumor associated macrophages to an anti-tumor state.

Contact:

Malin Deon

Tel: +1-857-259-3843

Email: mdeon@jouncetx.com

Latest news about Jounce Therapeutics, Inc.

Graphite Bio, Inc. Announces Executive Changes	23-08-23	CI
Jounce Therapeutics, Inc. Announces Board Changes	23-05-04	CI
Jounce Therapeutics, Inc.(NasdaqGS:JNCE) dropped from NASDAQ Composite Index	23-05-04	CI
Jounce Therapeutics, Inc.(NasdaqGS:JNCE) dropped from S&P Global BMI Index	23-05-04	CI
Jounce Therapeutics, Inc.(NasdaqGS:JNCE) dropped from S&P TMI Index	23-05-04	CI
Concentra Biosciences, LLC completed the acquisition of Jounce Therapeutics, Inc. from Tang Capital Management, LLC and others.	23-05-02	CI
Redx confirms Jounce deal lapses, Tirupati seals deal	23-04-03	AN
Redx Pharma Shares Fall 5% as Merger With Jounce Therapeutics Fails	23-04-03	MT
Jounce Therapeutics, Inc. Expects Resignation of Elizabeth Trehu as Chief Medical Officer	23-03-30	CI
Sector Update: Health Care Stocks Rise in Late Trading	23-03-27	MT
Sector Update: Health Care Stocks Higher in Afternoon Trading	23-03-27	MT
European Stock Markets Close Higher Monday as First Citizens BancShares' Planned Acquisition of Silicon Valley Bank Assets, Deposits Eases Banking Crisis Fears	23-03-27	MT
Piper Sandler Downgrades Jounce Therapeutics to Neutral From Overweight, Adjusts Price Target to $1.85 From $5	23-03-27	MT
Jounce dumps Redx Pharma for acquisition by Concentra; to cut 84% of jobs	23-03-27	RE
Redx Pharma Says Jounce Therapeutics Terminated Merger Deal; Shares Plunge 19%	23-03-27	MT
Jounce Therapeutics Agrees to be Acquired by Concentra Biosciences	23-03-27	MT
Redx Pharma's bid to buy Jounce snubbed by Concentra's higher offer	23-03-27	AN
Jounce Therapeutics, Inc. completed the acquisition of Redx Pharma Plc from a group of sellers and other shareholders.	23-03-26	CI
Jounce Therapeutics, Inc. Announces Results from Pre-Planned Data Review of INNATE Phase 2 Trial of JTX-8064 and Pimivalimab Demonstrating Deep and Durable Responses in Platinum Resistant Ovarian Cancer	23-03-16	CI
Sector Update: Health Care Stocks' Late Recovery Stalls	23-03-15	MT
Sector Update: Health Care Stocks Moderately Lower	23-03-15	MT
Top Midday Gainers	23-03-15	MT
Sector Update: Health Care Stocks Retreat Pre-Bell Wednesday	23-03-15	MT
Redx Pharma Says Merger Target Jounce Therapeutics Received New Takeover Proposal; Stock Surges 34%	23-03-15	MT
Sector Update: Health Care	23-03-15	MT

Chart Jounce Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company. It is engaged in the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients through a biomarker-driven approach. Its pipeline is focused on product candidates to address PD-(L)1-inhibitor resistant and PD-(L)1 inhibitor sensitive tumors. Its program, JTX-8064, is a tumor-associated macrophage candidate from its Translational Science platform. JTX-8064 is a monoclonal antibody that binds to Leukocyte Immunoglobulin Like Receptor B2, (LILRB2), which is a cell surface receptor expressed on macrophages and other myeloid cells. JTX-1484 is a monoclonal antibody designed to block human Leukocyte Immunoglobulin Like Receptor B4, (LILRB4) on various myeloid cells. Its product candidate, vopratelimab, is a monoclonal antibody that binds to and activates T cell CO-Stimulator (ICOS). It also develops JTX-1484 and JTX-2134 product candidates.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-2.35%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.71B
ARGENX SE	+1.69%	22.02B
BIONTECH SE	-17.13%	20.9B
GENMAB A/S	-9.30%	17.85B
WUXI APPTEC CO., LTD.	-41.01%	16.21B
BEIGENE, LTD.	-14.73%	15.52B
NEUROCRINE BIOSCIENCES, INC.	+3.07%	13.86B
SAREPTA THERAPEUTICS, INC.	+34.16%	12.04B

Bio Therapeutic Drugs